Drug intelligence / Profile preview

RJ7183

Development stage: Preclinical
Lead developer: Nanjing Ruijie Pharmaceutical Technology
Modality: Small Molecules

Overview

RJ7183 is a small molecule drug candidate currently under development by Nanjing Ruijie Pharma for the treatment of non-alcoholic steatohepatitis (NASH). While the drug is a key part of the company's metabolic pipeline, its specific biological target and detailed mechanism of action remain undisclosed by the developer. It is being developed alongside other NASH-targeted candidates such as RJ4287 and RJ4348, reflecting the company's focus on small molecule interventions for chronic liver and inflammatory diseases.

Beyond the preview

Go deeper on RJ7183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ7183.

Explore the full profile